I am pleased to share that today we announced the commercial launch of the MiniMed 670G system. Since earlier- than-expected FDA approval in September 2016, we have been working to ensure payer coverage, market and manufacturing readiness, as well as appropriate training of employees, clinicians, educators and patients on the new system. We also
I’m pleased to announce the start of our Customer Training Phase for the MiniMed 670G system. During this phase, we’ll focus on on-boarding a small group of Priority Access Program participants at a select number of healthcare provider sites across the country. These sites will reflect diversity in terms of practice type, size, experience
In September, we announced an incredibly exciting milestone that sent waves through the healthcare industry. The excitement and anticipation that we’ve seen in response to the FDA approval of the MiniMed 670G system is gratifying, both on a personal and professional level. We have the unique opportunity and privilege of introducing the first ever
This morning, we announced that data from the pivotal trial of our Hybrid Closed Loop (HCL) system were published in the Journal of the American Medical Association (JAMA) and concurrently presented at the annual meeting of the European Association for the Study of Diabetes (EASD). The data demonstrated the safety of the system and
I am thrilled to announce the U.S. launch of the MiniMed 630G system with SmartGuard technology – our most advanced pump platform for people with diabetes in the country. This latest innovation was developed through a collaborative process with the patient community, who provided feedback on features that matter most to people with diabetes.